Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $375.96M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.28M
Average 0.97M
INDP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Indaptus Therapeutics, Inc.NASDAQ: INDP
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$2.54M, compared with -$4.53M a year earlier. Trailing-twelve-month EBITDA was -$18.86M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -38.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.54M+68.7% QoQ
- Last fiscal yearDec 2025
- -$20.85M-38.8% YoY
- LTMMar 2026
- -$18.86M-19.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +43.9% | +100.0% | +56.1 pp |
| 1 year | -38.8% | +100.0% | +138.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (20.85M) USD
- Year-over-year change
- -38.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (20.85M) | -38.8% |
| FY2024 | 2024-12-31 | (15.02M) | +2.6% |
| FY2023 | 2023-12-31 | (15.42M) | -7.7% |
| FY2022 | 2022-12-31 | (14.32M) | -85.7% |
| FY2021 | 2021-12-31 | (7.71M) | — |
EBITDA vs competitors
How INDP compares with its peers on the latest reported figures
- INDP's LTM Mar 2026 EBITDA of -$18.86M is the lowest of the 2 companies compared; the peer median is -$5.1M.
- Its year-over-year change of -19.7% is the lowest of 2, against a peer median of +42.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | -$5.1M | +42.6% | — | — | |
| LTM Mar 2026 | -$18.86M | -19.7% | — | — | |
| Peer median (excluding INDP) | -$5.1M | +42.6% | — | — | |
Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.52M | 6.32M | 7.62M | 7.25M | 9.34M |
| Selling, General & Admin | 5.21M | 8.59M | 8.76M | 8.11M | 10.49M |
| Operating Expenses | 7.73M | 14.91M | 16.38M | 15.37M | 19.83M |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| EBITDA | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.73M) | (14.91M) | (16.38M) | (15.37M) | (19.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.72K | 588.11K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17.72K | 588.11K | 955K | 343.72K | (1.02M) |
| Income Before Tax | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| EPS (Diluted) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| Weighted Avg Shares | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
| Weighted Avg Shares (Diluted) | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
Indaptus Therapeutics, Inc.
NASDAQ:INDP
Intrinsic Alpha fair value
Locked
Current Price
$3.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.